Biomedicine · global
How a gut bacterial toxin pries open the colon barrier, with a key receptor finally emerging
A Nature study identifies claudin-4 as the first landing point for a cancer-associated gut bacterial toxin and intercepts the damage in mice with a decoy protein; this does not mean a cancer-prevention drug has arrived, but it turns a long-murky microbial carcinogenesis mechanism into a testable target.
Colon cancer is not only a story of a sequence of human genetic mutations. It may also begin with a mistaken contact between gut microbes and epithelial cells. For years, researchers have known that certain enterotoxigenic Bacteroides fragilis strains secrete Bacteroides fragilis toxin, abbreviated BFT, which damages the colonic epithelial barrier, triggers inflammation, and is associated with tumor formation; the real sticking point was which handle on the cell surface this toxin first grabs.
A study published in Nature now points the answer to claudin-4. The team used a genome-wide CRISPR screen to look for host factors required for BFT toxicity and found that when colonic epithelial cells lost claudin-4, BFT had more difficulty attaching and more difficulty cleaving E-cadherin; when claudin-4 expression was restored, the cells’ sensitivity to the toxin returned. E-cadherin is an important protein for maintaining adhesion among epithelial cells and barrier integrity. When it is cut, the barrier is more likely to loosen, giving inflammatory responses and abnormal proliferation an opening.
The significance of this discovery is that it connects previously scattered clues into a more complete causal chain. BFT itself is a metalloprotease, but previous experiments had long struggled to prove that it can directly cleave E-cadherin in a free state; the new model shows that claudin-4 may act like a positioning device, bringing the toxin to the cell-membrane surface and placing it near the site where E-cadherin is readily cleaved. The study also indicates that claudin-3 may partially stand in under certain conditions, a reminder that this pathway may not involve only a single receptor.
In terms of therapeutic possibilities, the team designed a soluble claudin-4 analogue to serve as a “decoy”: the toxin binds to the decoy first instead of binding to intestinal epithelial cells. ScienceDaily, citing information compiled by the research institution, reported that this molecule reduced BFT-induced colonic tissue damage in a mouse model; the animal experiments in the Nature paper showed that, after co-injection of the decoy protein, shedding of mouse cecal epithelial cells, edema, and loss of E-cadherin were all reduced.
However, this remains clearly distant from cancer prevention for use in humans. The mouse experiments used a model in which the toxin was delivered directly into the cecum, which is more suitable for testing mechanism and the concept of blockade, and cannot be equated with the clinical circumstances of long-term carriers or groups at high risk of colon cancer. The study also has not yet obtained an experimental structure showing the precise binding between BFT and claudin-4; the AlphaFold 3 model provided a possible pose, but the paper itself explicitly states that local confidence is insufficient, so atomic-level details cannot be treated as settled.
Another point requiring caution is that Bacteroides fragilis is itself a common member of the gut microbiota. Not all strains produce BFT, and carrying related strains does not mean cancer is inevitable. More precisely, this study uncovers the early steps by which one class of toxin-producing strains initiates epithelial injury and offers a more precise blocking direction than broad inhibition of metalloproteases.
If subsequent research can show that this claudin-binding site can be blocked safely and stably, related strategies may perhaps be extended to acute enterotoxigenic Bacteroides fragilis infection, or even become part of preventing microbe-associated colon cancer in high-risk groups. But the most important advance for now is moving “how gut bacteria drive cancerous change” from a broad association to a clear molecular point of contact: the toxin first grabs claudin-4 before it has a chance to tear open the epithelial barrier.